CORE LAB REPORTS FIRST QUARTER 2025 RESULTS
- REVENUE OF
$123.6 MILLION , DOWN 4% SEQUENTIALLY AND 5% YEAR-OVER-YEAR - OPERATING INCOME OF
$4.4 MILLION ; EX-ITEMS,$11.8 MILLION , DOWN 25% SEQUENTIALLY AND 21% YEAR-OVER-YEAR - OPERATING MARGINS, EX-ITEMS, OF 10%
- GAAP EPS OF
$0.00 ; EX-ITEMS,$0.14 , DOWN 35% SEQUENTIALLY, AND 25% YEAR-OVER-YEAR - FREE CASH FLOW OF
$3.9 MILLION , UP OVER 50% YEAR-OVER-YEAR - NET DEBT REDUCED BY
$4.9 MILLION ; DEBT LEVERAGE RATIO REMAINS AT 1.31 - COMPANY REPURCHASED 131,598 SHARES OF COMMON STOCK, A VALUE OF
$2.0 MILLION - COMPANY ANNOUNCES Q1 2025 QUARTERLY DIVIDEND
Core's CEO,
During the first quarter, Core Lab engaged with a number of new clients to pursue growth opportunities in the
Reservoir Description
Reservoir Description operations are closely correlated with trends in international and offshore activity levels, with approximately 80% of revenue sourced from projects originating outside the
Emerging unconventional plays continue to hold significant strategic importance for the future production plans of operators across the
Production Enhancement
Production Enhancement operations, which are focused on complex completions in unconventional oil and gas reservoirs in the
During the first quarter of 2025, Core Lab's Production Enhancement segment utilized its state-of-the-art product testing facility to engineer a remedy for potential stuck drill pipe on an offshore project in the
Also in the first quarter of 2025, a
Liquidity, Free Cash Flow, Share Repurchases, and Dividend
Core continues to focus on maximizing free cash flow ("FCF"), a non-GAAP financial measure defined as cash from operations less capital expenditures. For the first quarter of 2025, cash from operations was
As of
The Company will remain focused on executing its strategic business initiatives while also further reducing its leverage ratio. In addition, Core Lab will continue to evaluate allocation of capital and other uses of free cash to return value to shareholders.
On
On
Return On Invested Capital
The Board and the Company's Executive Management continue to focus on strategies that maximize return on invested capital ("ROIC") and FCF, factors that have high correlation to total shareholder return. Core's commitment to an asset-light business model and disciplined capital stewardship promote capital efficiency and are designed to produce more predictable and superior long-term ROIC.
The Board has established an internal metric to demonstrate ROIC performance relative to the oilfield service companies listed as Core's Comp Group by Bloomberg, as the Company continues to believe superior ROIC will result in higher total shareholder return. Using Bloomberg's formula, the Company's ROIC for the first quarter of 2025 was 8.3%.
Industry and Core Lab Outlook and Guidance
Recent tariffs announced by the
Core sees international project activity to be steady, with committed long-term upstream projects from the South Atlantic Margin, North and
Core Lab believes that the proposed tariffs will not apply to the vast majority of service revenue and product sales provided by the Company. Core Lab's services account for over 75% of the Company's total revenue, and are currently not subject to tariffs. Core's product sales have been less than 25% of total revenue, and are primarily manufactured in the
Reservoir Description's second quarter revenue is projected to range from
Core's second quarter 2025 revenue is projected to range from
The Company's second quarter 2025 guidance is based on projections for underlying operations and excludes gains and losses in foreign exchange. Although the first quarter of 2025 includes discrete items which increased the effective tax rate, the Company projects the effective tax rate for 2025 to be approximately 25%. Second quarter guidance assumes an effective tax rate of 25%.
Earnings Call Scheduled
The Company has scheduled a conference call to discuss Core's first quarter 2025 earnings announcement. The call will begin at
Core Laboratories Inc. is a leading provider of proprietary and patented reservoir description and production enhancement services and products used to optimize petroleum reservoir performance. The Company has over 70 offices in more than 50 countries and is located in every major oil-producing province in the world. This release, as well as other statements Core Lab makes, includes forward-looking statements regarding the Company's future revenue, profitability, business strategies and developments, demand for the Company's products and services and for products and services of the oil and gas industry generally, made in reliance upon the safe harbor provisions of Federal securities law. The Company's outlook is subject to various important cautionary factors, including risks and uncertainties related to the oil and natural gas industry, business and general economic conditions, including inflationary pressures, the impact on tariffs and sanctions, international markets, international political climates, including the
The Company undertakes no obligation to publicly update or revise any forward-looking statement to reflect events or circumstances that may arise after the date of this press release, except as required by law.
Visit the Company's website at www.corelab.com.
CORE LABORATORIES INC. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share data) (Unaudited)
| ||||||||||||||||
Three Months Ended | % Variance | |||||||||||||||
|
|
| vs. Q4-24 | vs. Q1-24 | ||||||||||||
REVENUE | $ | 123,585 | $ | 129,237 | $ | 129,637 | (4.4) % | (4.7) % | ||||||||
OPERATING EXPENSES: | ||||||||||||||||
Costs of services and product sales | 99,469 | 106,199 | 104,588 | (6.3) % | (4.9) % | |||||||||||
General and administrative expense | 13,647 | 9,080 | 11,789 | 50.3 % | 15.8 % | |||||||||||
Depreciation and amortization | 3,717 | 3,664 | 3,843 | 1.4 % | (3.3) % | |||||||||||
Other (income) expense, net | 2,335 | (3,880) | 846 | NM | 176.0 % | |||||||||||
Total operating expenses | 119,168 | 115,063 | 121,066 | 3.6 % | (1.6) % | |||||||||||
OPERATING INCOME | 4,417 | 14,174 | 8,571 | (68.8) % | (48.5) % | |||||||||||
Interest expense | 2,602 | 2,629 | 3,423 | (1.0) % | (24.0) % | |||||||||||
Income before income taxes | 1,815 | 11,545 | 5,148 | (84.3) % | (64.7) % | |||||||||||
Income tax expense | 1,746 | 4,076 | 1,658 | (57.2) % | 5.3 % | |||||||||||
Net income | 69 | 7,469 | 3,490 | (99.1) % | (98.0) % | |||||||||||
Net income attributable to non-controlling interest | 223 | 66 | 270 | NM | NM | |||||||||||
Net income (loss) attributable to Core Laboratories Inc. | $ | (154) | $ | 7,403 | $ | 3,220 | NM | NM | ||||||||
Diluted earnings per share | $ | — | $ | 0.16 | $ | 0.07 | NM | NM | ||||||||
Diluted earnings (loss) per share attributable to Core Laboratories Inc. | $ | — | $ | 0.15 | $ | 0.07 | NM | NM | ||||||||
Weighted average common shares outstanding - assuming dilution | 46,773 | 47,773 | 47,703 | (2.1) % | (1.9) % | |||||||||||
Effective tax rate | 96 | % | 35 | % | 32 | % | NM | NM | ||||||||
SEGMENT INFORMATION: | ||||||||||||||||
Revenue: | ||||||||||||||||
Reservoir Description | $ | 80,897 | $ | 86,793 | $ | 84,236 | (6.8) % | (4.0) % | ||||||||
Production Enhancement | 42,688 | 42,444 | 45,401 | 0.6 % | (6.0) % | |||||||||||
Consolidated | $ | 123,585 | $ | 129,237 | $ | 129,637 | (4.4) % | (4.7) % | ||||||||
Operating income: | ||||||||||||||||
Reservoir Description | $ | 2,339 | $ | 16,643 | $ | 6,892 | (85.9) % | (66.1) % | ||||||||
Production Enhancement | 1,503 | (2,597) | 1,576 | NM | (4.6) % | |||||||||||
Corporate and Other | 575 | 128 | 103 | NM | NM | |||||||||||
Consolidated | $ | 4,417 | $ | 14,174 | $ | 8,571 | (68.8) % | (48.5) % | ||||||||
"NM" means not meaningful | ||||||||||||||||
CORE LABORATORIES INC. & SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) (Unaudited)
| ||||||||||
% Variance | ||||||||||
ASSETS: |
|
| vs. Q4-24 | |||||||
Cash and cash equivalents | $ | 22,107 | $ | 19,157 | 15.4 % | |||||
Accounts receivable, net | 117,031 | 111,761 | 4.7 % | |||||||
Inventories | 59,031 | 59,402 | (0.6) % | |||||||
Other current assets | 30,599 | 36,286 | (15.7) % | |||||||
Total current assets | 228,768 | 226,606 | 1.0 % | |||||||
Property, plant and equipment, net | 97,943 | 97,063 | 0.9 % | |||||||
Right of use assets | 57,490 | 56,488 | 1.8 % | |||||||
Intangibles, goodwill and other long-term assets, net | 207,318 | 210,249 | (1.4) % | |||||||
Total assets | $ | 591,519 | $ | 590,406 | 0.2 % | |||||
LIABILITIES AND EQUITY: | ||||||||||
Accounts payable | $ | 38,497 | $ | 34,549 | 11.4 % | |||||
Short-term operating lease liabilities | 11,654 | 10,690 | 9.0 % | |||||||
Other current liabilities | 53,576 | 52,347 | 2.3 % | |||||||
Total current liabilities | 103,727 | 97,586 | 6.3 % | |||||||
Long-term debt, net | 124,367 | 126,111 | (1.4) % | |||||||
Long-term operating lease liabilities | 43,981 | 43,343 | 1.5 % | |||||||
Other long-term liabilities | 60,088 | 65,630 | (8.4) % | |||||||
Total equity | 259,356 | 257,736 | 0.6 % | |||||||
Total liabilities and equity | $ | 591,519 | $ | 590,406 | 0.2 % | |||||
CORE LABORATORIES INC. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited)
| ||||||||
Three Months Ended | ||||||||
2025 | 2024 | |||||||
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
Net income | $ | 69 | $ | 3,490 | ||||
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
Stock-based compensation | 4,159 | 4,820 | ||||||
Depreciation and amortization | 3,717 | 3,843 | ||||||
Deferred income taxes | (1,817) | 2,827 | ||||||
Accounts receivable | (5,938) | (6,290) | ||||||
Inventories | (272) | 991 | ||||||
Accounts payable | 2,971 | (551) | ||||||
Other adjustments to net income | 3,771 | (3,600) | ||||||
Net cash provided by operating activities | 6,660 | 5,530 | ||||||
CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
Capital expenditures - operations | (2,785) | (3,052) | ||||||
Capital expenditures - rebuilding of | (794) | — | ||||||
Net proceeds from insurance recovery | 3,121 | — | ||||||
Net proceeds on life insurance policies | — | 805 | ||||||
Other investing activities | 1,230 | 590 | ||||||
Net cash provided by (used in) investing activities | 772 | (1,657) | ||||||
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
Repayment of long-term debt | (15,000) | (17,000) | ||||||
Proceeds from long-term debt | 13,000 | 14,000 | ||||||
Dividends paid | (469) | (468) | ||||||
Repurchase of common shares | (2,022) | (44) | ||||||
Equity related transaction costs and other financing activities | 9 | (568) | ||||||
Net cash used in financing activities | (4,482) | (4,080) | ||||||
NET CHANGE IN CASH AND CASH EQUIVALENTS | 2,950 | (207) | ||||||
CASH AND CASH EQUIVALENTS, beginning of period | 19,157 | 15,120 | ||||||
CASH AND CASH EQUIVALENTS, end of period | $ | 22,107 | $ | 14,913 | ||||
Non-GAAP Information
Management believes that the exclusion of certain income and expenses enables it to evaluate more effectively the Company's operations period-over-period and to identify operating trends that could otherwise be masked by the excluded Items. For this reason, management uses certain non-GAAP measures that exclude these Items and believes that this presentation provides a clearer comparison with the results reported in prior periods. The non-GAAP financial measures should be considered in addition to, and not as a substitute for, the financial results prepared in accordance with GAAP, as more fully discussed in the Company's financial statements and filings with the Securities and Exchange Commission.
Reconciliation of Operating Income, Net Income (Loss) and Diluted Earnings (Loss) Per Share Attributable to Core Laboratories Inc. (In thousands, except per share data) (Unaudited)
| ||||||||||||
Operating Income | ||||||||||||
Three Months Ended | ||||||||||||
|
|
| ||||||||||
GAAP reported | $ | 4,417 | $ | 14,174 | $ | 8,571 | ||||||
Stock compensation (1) | 3,505 | (771) | 3,458 | |||||||||
Inventory and asset write-downs, lease abandonment and severance (2) | 3,416 | 4,115 | 2,633 | |||||||||
Gain on insurance recovery (3) | — | (2,572) | — | |||||||||
Foreign exchange losses (gains) | 480 | 761 | 285 | |||||||||
Excluding specific items | $ | 11,818 | $ | 15,707 | $ | 14,947 | ||||||
Net Income (Loss) Attributable to Core Laboratories Inc. | ||||||||||||
Three Months Ended | ||||||||||||
|
|
| ||||||||||
GAAP reported | ||||||||||||
Stock compensation (1) | 2,629 | (617) | 2,766 | |||||||||
Inventory and asset write-downs, lease abandonment and severance (2) | 2,562 | 3,292 | 2,106 | |||||||||
Gain on insurance recovery (3) | — | (2,058) | — | |||||||||
Foreign exchange losses (gains) | 360 | 610 | 229 | |||||||||
Effect of higher (lower) tax rate (4) | 1,292 | 1,766 | 628 | |||||||||
Excluding specific items | ||||||||||||
Diluted Earnings (Loss) Per Share Attributable to Core Laboratories Inc. | ||||||||||||
Three Months Ended | ||||||||||||
|
|
| ||||||||||
GAAP reported | $ | — | $ | 0.15 | $ | 0.07 | ||||||
Stock compensation (1) | 0.05 | (0.01) | 0.06 | |||||||||
Inventory and asset write-downs, lease abandonment and severance (2) | 0.05 | 0.07 | 0.04 | |||||||||
Gain on insurance recovery (3) | — | (0.04) | — | |||||||||
Foreign exchange losses (gains) | 0.01 | 0.01 | 0.01 | |||||||||
Effect of higher (lower) tax rate (4) | 0.03 | 0.04 | 0.01 | |||||||||
Excluding specific items | $ | 0.14 | $ | 0.22 | $ | 0.19 | ||||||
(1) Three months ended | ||||||||||||
(2) Three months ended | ||||||||||||
(3) Three months ended | ||||||||||||
(4) Three months ended | ||||||||||||
Segment Information (In thousands) (Unaudited)
| ||||||||||||
Operating Income | ||||||||||||
Three Months Ended | ||||||||||||
Reservoir | Production | Corporate and | ||||||||||
GAAP reported | $ | 2,339 | $ | 1,503 | $ | 575 | ||||||
Stock compensation | 2,360 | 1,145 | — | |||||||||
Inventory and asset write-downs, lease abandonment and severance | 2,869 | 547 | ||||||||||
Foreign exchange losses (gains) | 188 | 242 | 50 | |||||||||
Excluding specific items | $ | 7,756 | $ | 3,437 | $ | 625 | ||||||
Return on Invested Capital
Return on Invested Capital ("ROIC") is presented based on management's belief that this non-GAAP measure is useful information to investors and management when comparing profitability and the efficiency with which capital has been employed over time relative to other companies. The Board has established an internal metric to demonstrate ROIC performance relative to the oilfield service companies listed as Core's Comp Group by Bloomberg. ROIC is not a measure of financial performance under GAAP and should not be considered as an alternative to net income.
ROIC of 8.3% is defined by Bloomberg as Net Operating Profit After Tax ("NOPAT") of
Free Cash Flow
Core uses the non-GAAP financial measure of free cash flow to evaluate its cash flows and results of operations. Free cash flow is defined as net cash provided by operating activities (which is the most directly comparable GAAP measure) less cash paid for capital expenditures - operations. Management believes that free cash flow provides useful information to investors regarding the cash available in the period in excess of Core's needs to fund its capital expenditures and operating activities. Free cash flow is not a measure of operating performance under GAAP and should not be considered in isolation nor construed as an alternative to operating income, net income, or cash flows from operating, investing, or financing activities, each as determined in accordance with GAAP. Free cash does not represent residual cash available for distribution because Core may have other non-discretionary expenditures that are not deducted from the measure. Moreover, since free cash flow is not a measure determined in accordance with GAAP and thus is susceptible to varying interpretations and calculations, free cash flow as presented may not be comparable to similarly titled measures presented by other companies.
Computation of Free Cash Flow (In thousands) (Unaudited)
| |||||
Three Months Ended | |||||
Net cash provided by operating activities | $ | 6,660 | |||
Capital expenditures - operations | (2,785) | ||||
Free cash flow | $ | 3,875 | |||
View original content to download multimedia:https://www.prnewswire.com/news-releases/core-lab-reports-first-quarter-2025-results-302436442.html
SOURCE Core Laboratories Inc
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pfizer reports phase 2b results for monthly obesity drug berobenatide
- OPEC crude output drops to lowest level in 37 years
- The American Diabetes Association Announces Winners of the Innovation Challenge
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Oil Inventories, Dividend, Crude Oil, OPEC, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share